Reappraisal of fibrosis-4 index and non-alcoholic fatty liver disease fibrosis score for advanced fibrosis in average-risk population

Huiyul Park1†, Eileen L. Yoon2,3†, Mimi Kim4, Jonghyun Lee5, Seon Cho6, Dae Won Jun2,3,5‡ and Eun-Hee Nah6‡

1Department of Family Medicine, Myongji Hospital, Hanyang University College of Medicine, Seoul, South Korea, 2Department of Internal Medicine, Hanyang University College of Medicine, Seoul, South Korea, 3Hanyang Institute of Bioscience and Biotechnology, Hanyang University, Seoul, South Korea, 4Department of Radiology, Hanyang University College of Medicine, Seoul, South Korea, 5Department of Translational Medicine, Hanyang University Graduate School of Biomedical Science and Engineering, Seoul, South Korea, 6Department of Laboratory Medicine, Health Promotion Research Institute, Seoul, South Korea

Background and aim: The current cut-offs for fibrosis-4 (FIB-4) and non-alcoholic fatty liver disease fibrosis score (NFS) are suboptimal for screening because of low accuracy and high false-negative rates in average-risk populations. This study aimed to reappraisal the performance of FIB-4 and NFS in such average-risk populations.

Methods: This is a cross-sectional study, which retrospectively reviewed the magnetic resonance elastography (MRE) data of 8,522 subjects. Individuals with history of significant alcohol consumption and those with positive viral serologic markers were excluded. Finally, 6,215 average-risk individuals were analyzed.

Results: The area under the receiver operating characteristic curves (AUROCs) of FIB-4 for the diagnosis of advanced hepatic fibrosis was higher than that in the NFS especially in the metabolically healthy. The AUROCs of FIB-4 for in the average-risk population was also higher than that in the NFS (0.840 in FIB-4 vs. 0.798, \( P = 0.036 \)). However, the sensitivity of FIB-4 and NFS was low (69.6 and 61.4%, respectively) in applying the current cut-off of FIB-4 [1.3 (2.0)] and NFS [-1.455 (0.12)]. At cut-off of FIB-4 at 1.0, sensitivity (90.2%), and negative predictive value (99.7%) were improved.
Introduction

Socioeconomic burden of non-alcoholic fatty liver disease (NAFLD) has been increasing of late (1, 2). The most important risk factor for liver-related and overall mortality is the stage of hepatic fibrosis in patients with NAFLD (3, 4). Therefore, it is very important to screen and evaluate for the presence and severity of hepatic fibrosis in such patients (5–7). Prevalence of significant and advanced hepatic fibrosis in the general population is 5.1–9.5 and 1.3–2.6%, respectively (8, 9). Therefore, early detection of hepatic fibrosis in the general population is necessary to prevent liver-related events and to decrease medical costs. However, as no optimal screening algorithms and effective treatment for patients with NAFLD have yet been developed, screening for significant or advanced hepatic fibrosis is not recommended for general population.

Notably, health check-ups are extensively conducted for average-risk populations. Sonographic fatty liver and elevated liver enzyme levels are the most common reasons for referring patients from primary care centers to referral centers. However, the sensitivity of ultrasonography or biochemical tests for significant or advanced hepatic fibrosis is unsatisfactory. In recent times, the fibrosis-4 (FIB-4) index and non-alcoholic fatty liver disease fibrosis score (NFS) tests have become common as the first step to screen advanced hepatic fibrosis in individuals with known viral hepatitis and NAFLD (10). However, only one relevant large-scale study has been conducted for screening hepatic fibrosis in the general population (11). The study reported that FIB-4 and NFS were suboptimal for screening purposes because of the high risk of over-diagnosis in the general population (11). Therefore, special caution is needed when using the current low cut-off of FIB-4 or NFS as a single screening strategy in average-risk populations. New non-invasive methods or optimization of FIB-4 or NFS are needed for detecting fibrosis in low-prevalence fibrosis settings. However, the variables used in FIB-4 and NFS are generally already included in health check-up tests, and therefore, they do not require additional tests in primary care setting. Recent guidelines recommend to use FIB-4 and NFS over other non-invasive fibrosis markers as a first step screening tools, because they are mort well validated and have shown the best diagnostic accuracy among non-invasive fibrosis markers (10, 12). Moreover, considering that other tests (e.g., transient elastography) after FIB-4 and NFS are sequentially applied for the advanced hepatic fibrosis screening algorithm, FIB-4 and NFS tests as a first step are still attractive screening methods in primary care settings.

New cut-off or optimization of FIB-4 and NFS to reduce false-negatives and increase accuracy is needed for detecting fibrosis in low-prevalence fibrosis settings. This study is an attempt to conduct reappraisal the performance of FIB-4 or NFS and discuss the reasonable cut-off in average-risk populations.

Materials and methods

Study design

This was a retrospective, cross-sectional study. The subjects underwent magnetic resonance elastography (MRE) as part of their health check-up. The health check-up program was uniformly performed at 13 nationwide health-promotion centers. This study was approved by the institutional review board (IRB No. HY-2021-04-001-001) of Hanyang University Hospital, and the requirement for informed consent was waived.

Rationale for abdominal sonography and magnetic resonance elastography as health check-up

Abdominal sonography is one of the basic and most commonly performed health check-up examinations. It can be conducted either when the examinees prefer so or as part of an obligatory basic exam conducted every 1 or 2 years by companies under the Act of Employment in Korea. However, the MRE test is not included in the routine health check-up program. It is offered to patients as an additional option under their own expense. Patients with known chronic liver diseases are managed under a separate health check-up program run by the National Health Insurance Service in Korea. Therefore, they are less likely to be included in this study.
Inclusion and exclusion criteria

A total of 10,771 subjects who underwent MRE as part of their health check-up examination between January 1, 2017 and May 30, 2020 were included. Among them, 2,249 subjects were excluded owing to missing data on abdominal sonography and clinical information (e.g., metabolic risk abnormalities and variables used in FIB-4 and NFS). Individuals with history of significant alcohol consumption (≥210 g per week for men and ≥140 g per week for women) or chronic liver disease in the questionnaire and those with positive result in viral serologic markers (HBsAg and HCV Ab) were also excluded (n = 2,307) (Figure 1).

Clinical parameters of the subjects

Routine health check-up questionnaires were used to obtain the history of hypertension, diabetes mellitus (DM), or dyslipidemia and intake of the corresponding medications for these conditions, as well as the social history of alcohol intake. Anthropometric measurements included waist circumference, blood pressure, height, weight, total fat mass, and lean mass. Additionally, fasting serum glucose, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, AST, ALT, and γ-glutamyl transferase levels were measured.

FIB-4 and NFS were calculated, and their low cutoff values of FIB-4 [1.3 (2.0)] and NFS [−1.455 (0.12)] were selected according to the method described by McPherson et al. (13). If age of subjects was 65 or more, the cutoff values of FIB-4 (2.0) and NFS (0.12) were used. If age of subjects was lower than 65, the cutoff values of FIB-4 (1.3) and NFS (−1.455) were used.

Definition of metabolically healthy and unhealthy groups

We defined the metabolic risk abnormalities as follows (14): (1) waist circumference ≥ 85 cm for women and ≥ 90 cm for men, (2) blood pressure ≥ 130/85 mmHg and/or taking hypertension medication, (3) serum triglyceride ≥ 150 mg/dL, (4) high-density lipoprotein cholesterol < 50 mg/dL for women and < 40 mg/dL for men, and (5) fasting glucose level ≥ 100 mg/dL with HbA1c ≥ 5.7% and/or taking diabetes medication. The metabolically unhealthy group was defined as having diabetes or two or more metabolic risk abnormalities as per our previous study (15). The metabolically healthy group was defined as those with no diabetes and only one or no metabolic risk abnormality.

Assessment of fatty liver and hepatic fibrosis severity

The presence of fatty liver was evaluated using ultrasonography. Severity was graded as normal, mild, moderate, or severe according to the degree of fat infiltration.
(16). Liver echotexture, attenuation, and visualization of the intrahepatic vessel borders and/or the diaphragm were used as the indices. Liver stiffness was measured by MRE. All MRE examinations were performed on MRE hardware (GE Healthcare, Waukesha, Wisconsin, USA) with a 1.5-T imaging system using a two-dimensional MRE protocol (17). The acquired MRE images were automatically processed. Liver stiffness was assessed by a radiologist using regions of interest, excluding the vessels. The cut-off values for significant and advanced hepatic fibrosis were set at MRE values of ≥ 3.0 kPa (F2) and ≥ 3.6 kPa (F3), respectively (18). We used various cut-off values for advanced hepatic fibrosis for sensitivity analysis. The range of advanced fibrosis was defined as MRE values of 3.2–4.0 kPa for sensitivity analysis (19–23).

Statistical analyses

Continuous and categorical variables are presented as mean ± standard deviation and as numbers and percentages, respectively. Categorical variables were analyzed using either the χ²-test or Fisher’s exact test, whereas continuous variables were analyzed using Student’s independent t-test. Statistical analyses were performed using SPSS version 26.0 for Windows (SPSS Inc., Chicago, IL, USA). The area under the receiver operating characteristic (AUROC) curves of FIB-4 and NFS were compared using the independent χ²-test. Statistical analyses were performed using SPSS version 26.0 for Windows (SPSS Inc., Chicago, IL, USA). The area under the receiver operating characteristic (AUROC) curves of FIB-4 and NFS were compared using DeLong’s test in MedCalc version 20 (MedCalc Software Ltd., Ostend, Belgium). Statistical significance was set at P < 0.05.

Results

Baseline characteristics

A total of 6,215 average-risk subjects, who did not have chronic viral hepatitis and significant alcohol intake, were identified as the average-risk group for this study and were analyzed (Figure 1). These subjects had 26.4, 9.2, and 23.2% prevalence of hypertension, diabetes, and metabolic syndrome, respectively (Table 1). The prevalence of sonographic fatty liver in total, metabolic healthy, and unhealthy group was 47.7, 31.1, and 66.3%, respectively. The prevalence of significant and advanced hepatic fibrosis diagnosed according to MRE findings in this average-risk group was 6.6 and 1.6%, respectively. The proportion of metabolically healthy individuals in this average-risk group was 52.9%. The prevalence of significant and advanced hepatic fibrosis in the metabolically healthy group was 3.9 and 0.8%, respectively.

Comparison of diagnostic performance for advanced fibrosis between fibrosis-4 and NAFLD fibrosis score in the average-risk group

The AUROC of FIB-4 for the diagnosis of advanced hepatic fibrosis in the average-risk group was higher than that in

| Total subjects | Metabolically healthy group | Metabolically unhealthy group |
|----------------|-----------------------------|-------------------------------|
| Age (years)    | 47.5 ± 10.1                 | 45.9 ± 10                     | 49.3 ± 10                     | <0.001 |
| Male           | 5,031 (80.9)                | 2,514 (76.4)                  | 2,517 (86.1)                  | <0.001 |
| Hypertension   | 1,642 (26.4)                | 279 (8.5)                     | 1,363 (46.6)                  | <0.001 |
| Diabetes       | 571 (9.2)                   | 0 (0)                         | 571 (19.5)                    | <0.001 |
| Alcohol consumption (g/week) | 1.52 ± 1.29         | 0.49 ± 0.5                    | 2.68 ± 0.87                   | <0.001 |
| Number of metabolic risks† | 1.442 (23.2)         | 0 (0)                         | 1,442 (23.2)                  | <0.001 |
| Metabolic syndrome | 24.8 ± 3.2               | 23.4 ± 2.5                    | 26.3 ± 3.1                    | <0.001 |
| BMI (kg/m²)† | 85.5 ± 9                    | 81.2 ± 7.6                    | 90.2 ± 8                      | <0.001 |
| Waist circumference (cm)† | 116 ± 13                | 111 ± 11                      | 121 ± 13                      | <0.001 |
| SBP (mmHg)†   | 75 ± 9                      | 71 ± 8                        | 78 ± 9                        | <0.001 |
| DBP (mmHg)†   | 29 ± 17                     | 26 ± 14                       | 32 ± 19                       | <0.001 |
| ALT (IU/L)†   | 31 ± 29                     | 25 ± 25                       | 38 ± 31                       | <0.001 |
| GGT (U/L)†    | 55 ± 88                     | 41 ± 70                       | 71 ± 94                       | <0.001 |
| Triglyceride (mg/dL)† | 144 ± 111              | 100 ± 56                      | 194 ± 135                     | <0.001 |
| HDL (mg/dL)†  | 53 ± 13                     | 57 ± 12                       | 48 ± 11                       | <0.001 |
| Glucose (mg/dL)† | 99 ± 20                | 91 ± 8                        | 108 ± 25                      | <0.001 |
| FIB-4†        | 1.11 ± 0.6                  | 1.07 ± 0.53                   | 1.15 ± 0.68                   | <0.001 |
| NFS†          | -2.28 ± 1.2                 | -2.59 ± 1.09                  | -1.93 ± 1.21                  | <0.001 |
| Liver stiffness (kPa)† | 2.33 ± 0.58          | 2.27 ± 0.58                   | 2.4 ± 0.57                    | <0.001 |
| Sonographic fatty liver | 2,963 (47.7)        | 1,024 (31.1)                  | 1,939 (66.3)                  | <0.001 |
| Significant hepatic fibrosis | 411 (6.6)            | 129 (3.9)                     | 282 (9.6)                     | <0.001 |
| Advanced hepatic fibrosis | 102 (1.6)             | 25 (0.8)                      | 77 (2.6)                      | <0.001 |

Data are expressed as number (percent). † Data are shown as mean ± standard deviation. Metabolically healthy group was defined as having less than two metabolic risks and not having diabetes. AST, aspartate transaminase; ALT, alanine transaminase; BMI, body mass index; DBP, diastolic blood pressure; FIB-4, fibrosis-4 index; GGT, γ-glutamyl transferase; HDL, high-density lipoprotein; MRE, magnetic resonance elastography; NFS, non-alcoholic fatty liver disease fibrosis score; SBP, systolic blood pressure.
the NFS (0.840 in FIB-4 vs. 0.798, \(P = 0.036\)) (Figure 2A). A comparison of AUROCs of FIB-4 and NFS in the fatty-liver group (Figure 2C) and the metabolically unhealthy group (Figure 2E) did not show any difference in the diagnostic performance of FIB-4 and NFS. However, the AUROCs of FIB-4 in the non-fatty liver group (0.872 in FIB-4 vs. 0.777 in NFS, \(P = 0.010\)) and the metabolically healthy group (0.862 in FIB-4 vs. 0.702 in NFS, \(P = 0.001\)) were significantly higher than those of NFS (Figures 2B,D). FIB-4 was found to be better for diagnosing advanced hepatic fibrosis than NFS in the average-risk group, because a considerable number of metabolically healthy (52.9%) subjects were included in this category.

Sensitivity of fibrosis-4 and NAFLD fibrosis score to screen advanced fibrosis in the average-risk group

When we used the current cut-off of FIB-4 [1.3 (2.0)] and NFS [-1.455 (0.12)] for diagnosing advanced fibrosis (MRE value \(\geq 3.6\) kPa), the sensitivity and positive predictive value (PPV) were found to be lower under most conditions (Figure 3 and Table 2). FIB-4 and NFS had low sensitivity (69.6 and 61.4%, respectively). In addition, the sensitivity of NFS further decreased in metabolically healthy (44.0%) and non-fatty liver (59.0%) groups when we applied the current low cut-off. The diagnostic performance of FIB-4 for advanced hepatic fibrosis was evaluated at different cut-off values (Table 3). As the cut-off value was increased from 0.9 to 1.3, the sensitivity decreased from 92.2 to 75.5% in the average-risk group. When the low cut-off of FIB-4, used as a first screening test for advanced hepatic fibrosis in the average-risk group, was lowered to 1.0, the sensitivity was 90.2% and the negative predictive value was 99.7%.

Sensitivity analysis for diagnostic performance of fibrosis-4 in patients with specific conditions

Sensitivity analysis of the AUROCs of FIB-4 and NFS using various cut-off values for MRE (3.2–4.0 kPa) was performed (Table 4 and Figure 4). The AUROC of FIB-4 for hepatic fibrosis using various cut-off values for MRE (3.2–4.0 kPa) in an average-risk population was 0.709–0.896 (Table 4). Notably, the AUROC of FIB-4 for diagnosing hepatic fibrosis in the
metabolically healthy group at different cut-off values for MRE was significantly higher than that of NFS, except for the cut-off value at 4.0 kPa (Figure 4). However, no difference in AUROCs was noted between FIB-4 and NFS in both the fatty liver and metabolically unhealthy groups at all cut-off values (Table 4).

Discussion

Hepatic fibrosis, which is important risk factor in the prognosis of NAFLD patients is related not only to traditional TGF-β pathway, but also FOSL2, ADAM17, and angiotensin pathway. It is very important to identify high-risk groups by assessing the stage of hepatic fibrosis in suspected NAFLD patients. Currently, most guidelines recommend use of FIB-4 or NFS as a test for screening advanced liver fibrosis patients. We evaluated the diagnostic performance of FIB-4 and NFS in the average-risk group. The diagnostic performance of both FIB-4 (AUROC: 0.840) and NFS (AUROC: 0.798) was good even in the average-risk group. The diagnostic performance of FIB-4 was better than that of NFS for screening hepatic fibrosis in the average-risk group, while it was comparable to that of NFS in the metabolically healthy group. However, the diagnostic performance of the NFS decreased in the metabolically healthy and non-fatty liver groups. Because the current FIB-4 low cut-off has low accuracy and leads to false-negative results, it cannot be used as a single screening strategy in the average-risk group. Although diagnostic performance of FIB-4 was good, our large cohort reconfirmed considerable proportion of false-negative subjects with FIB-4 and very low PPV in the average-risk population. Currently, routine screening for advanced hepatic fibrosis is not recommended in general and average-risk populations. However, given that a considerable proportion of the general and average-risk population undergo health check-ups, a screening for hepatic fibrosis must be performed for those individuals who have already undergone medical check-ups based on a reasonable referral algorithm. Although the accuracy and positive-predictive value of FIB-4 are still not satisfactory, physicians can calculate FIB-4 using the pre-existing health check-up test item at no additional cost. FIB-4 can be a very attractive first screening method in a medical check-up setting, because additional sequential test can back-up the low positive-predictive value. Therefore, if we can increase the sensitivity of FIB-4 by adjusting the low cut-off values, FIB-4 can become...
TABLE 2 Comparison of FIB-4 and NFS for diagnostic performance of advanced hepatic fibrosis in various groups.

|                      | Advanced fibrosis* | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
|----------------------|--------------------|-----------------|-----------------|---------|---------|
| **FIB-4 to use low cut-off; 1.3 (2.0)** |                    |                 |                 |         |         |
| Total subjects       | 102 (2.6)          | 69.6            | 77.5            | 4.9     | 99.3    |
| Non-fatty liver group| 39 (1.2)           | 71.8            | 76.7            | 3.6     | 99.6    |
| Metabolically healthy group | 25 (0.8) | 64.0            | 78.2            | 2.2     | 99.6    |
| Fatty liver group    | 63 (2.1)           | 68.3            | 78.4            | 6.4     | 99.1    |
| Metabolically unhealthy group | 77 (2.6) | 71.4            | 76.7            | 7.7     | 99.0    |
| **NFS to use low cut-off; -1.455 (0.12)** |                    |                 |                 |         |         |
| Total subjects       | 102 (2.6)          | 61.4            | 81.1            | 5.2     | 99.2    |
| Non-fatty liver group| 39 (1.2)           | 59.0            | 82.6            | 4.0     | 99.4    |
| Metabolically healthy group | 25 (0.8) | 44.0            | 89.0            | 3.0     | 99.5    |
| Fatty liver group    | 63 (2.1)           | 62.9            | 79.5            | 6.2     | 99.0    |
| Metabolically unhealthy group | 77 (2.6) | 67.1            | 72.1            | 6.1     | 98.8    |

*Prevalence of subjects with advanced hepatic fibrosis among total subjects (n = 6,215), and the non-fatty liver (n = 3,252), metabolically healthy (n = 3,291), fatty liver (n = 2,963), and metabolically unhealthy (n = 2,924) groups. FIB-4, fibrosis-4 index; MRE, magnetic resonance elastography; NFS, non-alcoholic fatty liver disease fibrosis score; PPV, positive predictive value; NPV, negative predictive value.

The most cost-effective first-line screening test in average-risk populations.

FIB-4 and NFS have different variables because of different disease entities of the target population at the time of development. Clinical characteristics between two cohorts are very different only when their average BMIs (25 vs. 32) are compared (28, 29). Therefore, metabolic components such as BMI and the presence of impaired fasting glycemia or diabetes were included as variables only in the NFS formula. Consequently, the diagnostic performance of NFS is more easily affected by the metabolic status of the target population than that of FIB-4.

Interestingly, FIB-4 as an indicator of hepatic fibrosis worked well when applied to not only the fatty liver group (AUROC = 0.823) but also the non-fatty liver group (AUROC = 0.872) or metabolically healthy group (AUROC = 0.862). Conversely, the AUROCs of NFS in the non-fatty liver group (AUROC = 0.777) and metabolically healthy group (AUROC = 0.702) were lower or comparable to those in the fatty-liver group (AUROC = 0.800). Both FIB-4 and NFS have been validated well in patients with fatty liver or metabolic unhealthy. So, it makes sense that all of FIB-4 and NFS work well in subjects with fatty liver or metabolic unhealthy. However, the validation of FIB-4 and NFS especially in non-fatty liver or metabolic healthy has been very limited.

TABLE 3 Comparison of diagnostic performance for advanced hepatic fibrosis (MRE cut-off values ≥ 3.6) according to the various cut-off values of FIB-4.

|                      | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Accuracy (%) |
|----------------------|-----------------|-----------------|---------|---------|--------------|
| **FIB-4 to use low cut-off; 1.3 (2.0)** |                    |                 |         |         |              |
| Total subjects       | 69.6            | 77.5            | 4.9     | 99.3    | 77.4         |
| Metabolically healthy group | 64.0 | 78.2            | 2.2     | 99.6    | 78.1         |
| **FIB-4 to use low cut-off; 0.9** |                    |                 |         |         |              |
| Total subjects       | 92.2            | 42.1            | 2.6     | 99.7    | 42.9         |
| Metabolically healthy group | 100.0 | 43.6            | 1.3     | 100     | 44.0         |
| **FIB-4 to use low cut-off; 1.0** |                    |                 |         |         |              |
| Total subjects       | 90.2            | 52.2            | 3.1     | 99.7    | 52.8         |
| Metabolically healthy group | 96.0 | 53.8            | 1.6     | 99.9    | 54.1         |
| **FIB-4 to use low cut-off; 1.1** |                    |                 |         |         |              |
| Total subjects       | 87.3            | 60.9            | 3.6     | 99.7    | 61.3         |
| Metabolically healthy group | 92.0 | 61.9            | 1.8     | 99.9    | 62.2         |
| **FIB-4 to use low cut-off; 1.2** |                    |                 |         |         |              |
| Total subjects       | 83.3            | 69.0            | 4.3     | 99.6    | 69.2         |
| Metabolically healthy group | 80.0 | 69.8            | 2.0     | 99.8    | 69.9         |
| **FIB-4 to use low cut-off; 1.3** |                    |                 |         |         |              |
| Total subjects       | 75.5            | 75.4            | 4.9     | 99.5    | 75.4         |
| Metabolically healthy group | 76.0 | 76.7            | 2.4     | 99.8    | 76.7         |

Our results showed the AUROC of FIB-4 in metabolic healthy was even higher than that in metabolic unhealthy. The inverse tendency was also observed in NFS. Moreover, nearly 53% of total subjects were metabolically healthy. That is why the AUROC of FIB-4 was also significantly higher than that of NFS in all subjects (0.840 in FIB-4 vs. 0.798 in NFS, P = 0.036). Therefore, FIB-4 use should be recommended for screening subjects with hepatic fibrosis burden in average-risk groups.

Careful interpretation of the results obtained is required for several reasons. Most importantly, hepatic societies do not recommend routine screening for hepatic fibrosis in subjects without a risk of advanced hepatic fibrosis. We completely understand the concerns about unnecessary examinations. However, a non-negligible number of subjects with hepatic fibrosis (0.3–2.1%; MRE cut-off value = 3.2–4.0 kPa) were present in our cohort, although they were metabolically healthy and had no risk of viral and alcoholic hepatitis. The prevalence of hepatic fibrosis in all subjects was 0.9–3.9% (MRE cut-off values


disease entities of the target population at the time of development. Clinical characteristics between two cohorts are very different only when their average BMIs (25 vs. 32) are compared (28, 29). Therefore, metabolic components such as BMI and the presence of impaired fasting glycemia or diabetes were included as variables only in the NFS formula. Consequently, the diagnostic performance of NFS is more easily affected by the metabolic status of the target population than that of FIB-4.

Interestingly, FIB-4 as an indicator of hepatic fibrosis worked well when applied to not only the fatty liver group (AUROC = 0.823) but also the non-fatty liver group (AUROC = 0.872) or metabolically healthy group (AUROC = 0.862). Conversely, the AUROCs of NFS in the non-fatty liver group (AUROC = 0.777) and metabolically healthy group (AUROC = 0.702) were lower or comparable to those in the fatty-liver group (AUROC = 0.800). Both FIB-4 and NFS have been validated well in patients with fatty liver or metabolic unhealthy. So, it makes sense that all of FIB-4 and NFS work well in subjects with fatty liver or metabolic unhealthy. However, the validation of FIB-4 and NFS especially in non-fatty liver or metabolic healthy has been very limited.

Our results showed the AUROC of FIB-4 in metabolic healthy was even higher than that in metabolic unhealthy. The inverse tendency was also observed in NFS. Moreover, nearly 53% of total subjects were metabolically healthy. That is why the AUROC of FIB-4 was also significantly higher than that of NFS in all subjects (0.840 in FIB-4 vs. 0.798 in NFS, P = 0.036). Therefore, FIB-4 use should be recommended for screening subjects with hepatic fibrosis burden in average-risk groups.

Careful interpretation of the results obtained is required for several reasons. Most importantly, hepatic societies do not recommend routine screening for hepatic fibrosis in subjects without a risk of advanced hepatic fibrosis. We completely understand the concerns about unnecessary examinations. However, a non-negligible number of subjects with hepatic fibrosis (0.3–2.1%; MRE cut-off value = 3.2–4.0 kPa) were present in our cohort, although they were metabolically healthy and had no risk of viral and alcoholic hepatitis. The prevalence of hepatic fibrosis in all subjects was 0.9–3.9% (MRE cut-off values 3.2–4.0 kPa). Moreover, the global hepatic fibrosis burden is gradually increasing owing to an increase in metabolic diseases. Therefore, preliminary studies for screening subjects with hepatic fibrosis burden in the general and average-risk populations are needed. Our study is the first step in this regard.
Advanced fibrosis (LSM ≥ 12 kPa) by using a low cutoff value of FIB-4 (1.90% vs. 23.97%) and NFS (2.57% vs. 29.27%) in general population, compared to those in the high risk group. PPV and NPV are affected by the prevalence of disease. In the case of general population, whose disease prevalence is low, the low PPV is expected. In our study on average-risk subjects, similar PPV (4.9% in FIB-4, 5.9% in NFS) was observed when the current cut-off values were used. Non-negligible false-positive rates in FIB-4 (22.12%) and (18.56%) are observed (Figure 3). The accuracy of the current FIB-4 low cut-off was not satisfactory to be used as a single screening strategy in the average-risk group.

However, the screening strategy in the general population should focus on not missing patients with high hepatic fibrosis burden and finding subjects who can be managed through intensive lifestyle modification at the primary care center. If we consider this purpose, then we believe that the current low PPV and high false-positive rate can be tolerated, and even the lower cut-off values with relaxed standard are more appropriate for the general population. Shah et al. also suggested that a cut-off of 1.0 in FIB-4 can be appropriate for a primary care referral pathway (30). Our data also showed an increase in sensitivity (69.6–90.2% in total subjects; 64.0–96.0% in the metabolically healthy group) and comparable PPV and NPV when the cut-off value of 1.0 was used instead of using the previous optimal cut-off value [1.3 (2.0)], although more subjects without hepatic fibrosis were identified as positive (47.03% vs. 22.12%) (Figure 3). It is difficult to suggest what is the optimal cut-off value of FIB-4 for screening advanced hepatic fibrosis in general population based on our study alone. Another validation study for the new cut-off value and the socioeconomic assessment for application of FIB-4 for screening advanced hepatic fibrosis in general population should be needed in the future.

This study has some limitations as well. First, MRE, not liver biopsy, was performed to evaluate the degree of hepatic fibrosis. When comparing the diagnostic performance, the use of gold standard methods such as liver biopsy is necessary. However, it is impossible to routinely perform such methods in a health check-up setting. In this study, we evaluated MRE data because it is the most reliable non-invasive diagnostic method for estimating liver stiffness. Second, the proportion of men was higher than that of women in the study cohort. Moreover, there is a possibility that people concerned with liver health were more likely to be included in study, because MRE was offered as an additional option to be tested with their own expense. There is a possibility of selection bias. Large number of excluded subjects (n = 2,249) due to missing data can be another source of selection bias. Nevertheless, the overall prevalence of hypertension (26.4%), DM (9.2%), and metabolic syndrome (23.2%) was comparable to that in the general population. Third, there is no consensus on MRE cut-off values for advanced hepatic fibrosis. In this study, an MRE cut-off value of 3.6 kPa was used for advanced fibrosis. However, a similar result was obtained when the MRE cut-off value was set at either 3.2 or 4.0 kPa in the sensitivity analysis. Therefore, we believe that our results are reliable regardless of the cut-off values.

In conclusion, the AUROCs of FIB-4 and NFS for advanced fibrosis did not differ between the metabolically unhealthy and fatty liver groups. However, the AUROC of FIB-4 for advanced fibrosis was higher than that of NFS, particularly in the average-risk group.

Further study of the current cut-off values of FIB-4 for the average-risk group is needed. The current cut-off values proposed by McPherson et al. were originally optimized for screening subjects with advanced hepatic fibrosis among high-risk groups, such as those with fatty liver, viral hepatitis, and significant alcohol intake. A recent study reported that the FIB-4 and NFS have low accuracy for screening liver fibrosis in the general population (11). They pointed out the lower PPV for advanced fibrosis (LSM ≥ 12 kPa) by using a low cutoff value of FIB-4 (1.90% vs. 23.97%) and NFS (2.57% vs. 29.27%) in general population, compared to those in the high risk group. PPV and NPV are affected by the prevalence of disease. In the case of general population, whose disease prevalence is low, the low PPV is expected. In our study on average-risk subjects, similar PPV (4.9% in FIB-4, 5.9% in NFS) was observed

### TABLE 4 Comparison of AUROC for hepatic fibrosis between FIB-4 and NFS in various groups according to different MRE cut-off values.

| MRE cut-off | AUROC | P-value |
|------------|-------|---------|
|            | FIB-4 | NFS     |
| Total      | 3.2   | 0.709   | 0.699 | 0.803 |
|            | 3.4   | 0.751   | 0.745 | 0.761 |
|            | 3.6   | 0.840   | 0.798 | 0.036 |
|            | 3.8   | 0.867   | 0.843 | 0.174 |
|            | 4.0   | 0.896   | 0.877 | 0.529 |
| Non-fatty liver group | 3.2 | 0.728 | 0.682 | 0.151 |
|            | 3.4   | 0.759   | 0.706 | 0.129 |
|            | 3.6   | 0.872   | 0.777 | 0.01  |
|            | 3.8   | 0.925   | 0.867 | 0.122 |
|            | 4.0   | 0.933   | 0.900 | 0.467 |
| Metabolically healthy group | 3.2 | 0.732 | 0.631 | <0.001 |
|            | 3.4   | 0.756   | 0.638 | 0.001 |
|            | 3.6   | 0.862   | 0.702 | 0.001 |
|            | 3.8   | 0.913   | 0.808 | 0.03  |
|            | 4.0   | 0.956   | 0.880 | 0.105 |
| Fatty liver group | 3.2 | 0.704 | 0.704 | 0.706 |
|            | 3.4   | 0.752   | 0.76   | 0.671 |
|            | 3.6   | 0.823   | 0.806 | 0.389 |
|            | 3.8   | 0.841   | 0.824 | 0.336 |
|            | 4.0   | 0.876   | 0.860 | 0.622 |
| Metabolically unhealthy group | 3.2 | 0.695 | 0.668 | 0.984 |
|            | 3.4   | 0.744   | 0.742 | 0.899 |
|            | 3.6   | 0.828   | 0.800 | 0.08  |
|            | 3.8   | 0.85    | 0.823 | 0.111 |
|            | 4.0   | 0.878   | 0.852 | 0.346 |

Metabolically healthy group was defined as sharing less than two metabolic risks and not having diabetes. AUROC, area under the receiver operating characteristic curve; FIB-4, fibrosis-4 index; MRE, magnetic resonance elastography; NFS, non-alcoholic fatty liver disease fibrosis score.
metabolically healthy and non-fatty liver groups. As more than half the average-risk population were consisted of metabolically healthy individuals, FIB-4 showed better performance for diagnosing advanced fibrosis when applied to the whole group with average-risk. It is recommended to use FIB-4 rather than NFS, when screening for hepatic fibrosis in general population.

Data availability statement

The original contributions presented in this study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

Ethics statement

The studies involving human participants were reviewed and approved by the Institutional Review board (IRB No. HY-2021-04-001-001) of Hanyang University Hospital. The ethics committee waived the requirement of written informed consent for participation.

Author contributions

DJ: concept, design, and interpretation of data. EY, JL, MK, SC, and E-HN: data collection and management. HP: writing of the manuscript. DJ and E-HN: supervision. All authors read and approved the manuscript.

Funding

This work was supported by the Research Program funded by the Korea National Institute of Health (grant no. 2022-ER0906-00).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References

1. Paik JM, Kabbaza K, Eberly KE, Younossi Y, Henry L, Younossi ZM. Global burden of NAFLD and chronic liver disease among adolescents and young adults. Hepatology. (2022): 75:1204–14. doi: 10.1002/hep.32228
2. Estes C, Chan HL, Chien RN, Chuang WL, Fung J, Goh GB-B, et al. Modelling NAFLD disease burden in four Asian regions in 2019–2030. Aliment Pharmacol Ther. (2020) 51:801–11. doi: 10.1111/apt.15673
3. Dulai PS, Singh S, Patel J, Somi M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. (2017): 65:1557–65. doi: 10.1002/hep.29085
4. Vilar-Gomez E, Calahadilla-Bertot L, Wong VW S, Castellanos M, Aller-de la Fuente R, Metwally M, et al. Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterology. (2018) 155:443–57.e17. doi: 10.1053/j.gastro.2018.04.034
5. European Association for the Study of the Liver [EASL], European Association for the Study of Diabetes [EASD], European Association for the Study of Obesity [EASO]. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Obesity Facts. (2016) 9:65–90. doi: 10.1159/000433444
6. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rine M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. (2018) 67:328–57. doi: 10.1002/hep.29367
7. Oh H, Jun DW, Saeed WK, Nguyen MH. Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment. Clin Mol Hepatol. (2016) 22:327. doi: 10.3334/cmhe.2016.0049
8. Kang KA, Jun DW, Kim MS, Kwon HJ, Nguyen MH. Prevalence of significant hepatic fibrosis using magnetic resonance elastography in a health check-up clinic population. Aliment Pharmacol Ther. (2020) 51:388–96. doi: 10.1111/apt.16526
9. Nab E-H, Cho S, Kim S, Chu J, Kwon E, Cho H-J. Prevalence of liver fibrosis and associated risk factors in the Korean general population: a retrospective cross-sectional study. BMJ Open. (2021) 11:e046529. doi: 10.1136/bmjopen-2020-046529
10. Panel CPG, Benzigotti A, Tschoschitz A, Bourjer M, Castor L, Cazzagon N, et al. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis—2021 update. J Hepatol. (2021) 75:659–89. doi: 10.1016/j.jhep.2021.05.025
11. Graupera I, Thiele M, Serra-Burriel M, Caballera L, Roulot D, Wong GL, H, et al. Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population. Clin Gastroenterol Hepatol. (2021) 21:542-536:1558–1356. doi: 10.1016/j.cgh.2021.12.034
12. Kanwal F, Shrubook JH, Adams LA. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology. (2021) 161:1657–69. doi: 10.1053/j.gastro.2021.07.049
13. McPherson S, Hardy T, Dufour JP, Petta S, Romero-Gomez M, Allison M, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD Fibrosis. Am J Gastroenterol. (2017) 112:740–51. doi: 10.1038/ajg.2016.453
14. Alberti K, Ecker RH, Grundy SM, Zimmet PP, Cleeman JI, Donato KA, et al. Harmonising the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention, national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation. (2009) 120:1640–5. doi: 10.1161/CIRCULATIONAHA.109.192644
15. Park H, Yoon EL, Kim M, Cho S, Kim J-H, Jun DW, et al. Selecting the target population for screening of hepatic fibrosis in primary care centers in Korea. J Clin Med. (2022) 11:1474. doi: 10.3390/jcm11061474
16. Mittelstaedt C. General ultrasound. New York: Churchill (1992).
17. Yin M, Talwalkar JA, Glaser KJ, Manduca A, Grimm RC, Rossman PJ, et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol. (2007) 5:1207–13.e2. doi: 10.1016/j.cgh.2007.06.012
18. Hsu C, Caussy C, Imajo K, Chen J, Singh S, Kaulback K, et al. Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants. Clin Gastroenterol Hepatol. (2019) 17:630–7.e7. doi: 10.1016/j.cgh.2018.05.059
19. Cui J, Heba E, Hernandez C, Haufe W, Hooker J, Andre MP, et al. MRE is superior to ARFI for the diagnosis of fibrosis in patients with biopsy-proven NAFLD: a prospective study. Hepatology. (2016) 63:453. doi: 10.1002/hep.23237
20. Furlan A, Tablin ME, Yu L, Chopra KB, Lippello A, Behari J. Comparison of 2D shear wave elastography, transient elastography, and MR elastography for the diagnosis of fibrosis in patients with nonalcoholic fatty liver disease. Am J Roentgenol. (2020) 214:W20–6. doi: 10.2214/AJR.19.21267
21. Lee Y-S, Yoo YJ, Jung YK, Kim JH, Seo YS, Yim HJ, et al. Multiparametric MR is a valuable modality for evaluating disease severity of nonalcoholic fatty liver disease. Clin Trans Gastroenterol. (2020) 11:4. doi: 10.14309/ctg.00000000000157
22. Loomba R, Cui J, Wolfson T, Haufe W, Hooker J, Stevrenen Y, et al. Novel 3D magnetic resonance elastography for the noninvasive diagnosis of advanced fibrosis in NAFLD: a prospective study. Am J Gastroenterol. (2016) 111:986. doi: 10.1038/ajg.2016.65
23. Imajo K, Honda Y, Kobayashi T, Nagai K, Ozaki A, Iwaki M, et al. Direct comparison of US and MR elastography for staging liver fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. (2020) 20:908–17.e11. doi: 10.1016/j.cgh.2019.12.016
24. Hu P-X, Sheng M-Y, Liu Y-P. FOSL2 deficiency delays nonalcoholic steatohepatitis progression by regulating LYSMediated NLRP3 activation. Hum Cell. (2022) 2022:1–14. doi: 10.1016/j.humc.2021.05.076
25. Xue F, Cheng J, Liu Y. Cardiomyocyte-specific knockout of ADAM17 ameliorates left ventricular remodeling and function in diabetic cardiomyopathy of mice. Signal Trans Target Ther. (2022) 7:1–6. doi: 10.1038/s41392-021-0054-3
26. Zhang M, Sui W, Xing F. Angiotensin IV attenuates diabetic cardiomyopathy via suppressing FoxO1-induced excessive autophagy, apoptosis and fibrosis. Theranostics. (2021) 11:8624. doi: 10.7150/thno.48561
27. Park H, Yoon EL, Kim M. Selecting the target population for screening of hepatic fibrosis in primary care centers in Korea. J Clin Med. (2022) 11:1474.
28. Sterling RK, Lissen E, Cluneck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV co-infection. Hepatology. (2006) 43:1317–25. doi: 10.1002/hep.21178
29. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. (2007) 45:846–54. doi: 10.1002/hep.21496
30. Shah S, Dhami-Shah H, Kamble S, Shukla A. FIB-4 cut-off of 1.3 may be inappropriate in a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol. (2020) 73:216–7. doi: 10.1016/j.jhep.2019.12.025

Frontiers in Medicine 10